SH3GL2: A Potential Drug Target and Biomarker (G6456)

Target Name: SH3GL2

NCBI ID: G6456

SH3GL2

SH3GL2: A Potential Drug Target and Biomarker

SH3GL2, also known as bA335L15.1 (SH3-domain GRB2-like 2), is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases.

SH3GL2 was identified as a protein that was expressed in a variety of tissues and organs, including brain, muscle, liver, and pancreas. It is characterized by a unique SH3 domain, which is known for its ability to interact with other proteins and molecules. The SH3 domain is composed of a single amino acid, which is responsible for the protein's unique structure and function.

One of the key features of SH3GL2 is its ability to interact with the protein GRB2. GRB2 is a gene that is known to play a role in the regulation of cell growth and differentiation. It is also a known interactor with the SH3 domain, which suggests that SH3GL2 may have important functions in these processes.

In addition to its potential interactions with GRB2, SH3GL2 has also been shown to interact with several other proteins, including the transcription factor NF-kappa-B. This suggests that SH3GL2 may have important roles in the regulation of gene expression and cellular processes.

The potential functions of SH3GL2 as a drug target are significant. SH3GL2 has been shown to be involved in a variety of cellular processes, including cell growth, differentiation, and inflammation. It is also involved in the regulation of cell survival and has been shown to play a role in the development of cancer.

In addition to its potential functions as a drug target, SH3GL2 has also been identified as a potential biomarker. Its unique structure and function make it a potential diagnostic tool for a variety of diseases. For example, SH3GL2 has been shown to be expressed in a variety of cancer types, including breast, lung, and ovarian cancer. This suggests that it may be a useful biomarker for the diagnosis and monitoring of these diseases.

In conclusion, SH3GL2 is a protein that has significant potential as a drug target and biomarker. Its unique structure and function make it an attractive target for research into the regulation of cellular processes and the development of disease. Further studies are needed to fully understand its potential functions and to determine its potential as a drug.

Protein Name: SH3 Domain Containing GRB2 Like 2, Endophilin A1

Functions: Implicated in synaptic vesicle endocytosis. May recruit other proteins to membranes with high curvature. Required for BDNF-dependent dendrite outgrowth. Cooperates with SH3GL2 to mediate BDNF-NTRK2 early endocytic trafficking and signaling from early endosomes

The "SH3GL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3GL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets